newsfilter
← Latest News
Business Wire·

Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease

GPH101 designed to directly correct the genetic mutation responsible for sickle cell disease First patient expected to be treated in first half of 2022, with initial proof-of-concept data anticipated by end of 2022 Graphite Bio, Inc. (NASDAQ:GRPH)